SLN (Silence Therapeutics) Shiller PE Ratio: (As of Sep. 12, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SLN Silence Therapeutics PLC SLN
36 GF Score
Price $13.05
GF Value $0.07
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Silence Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Silence Therapeutics  (NAS:SLN) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Silence Therapeutics Shiller PE Ratio Related Terms


Silence Therapeutics Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Silence Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Silence Therapeutics Shiller PE Ratio Chart

Silence Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Silence Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

SLN vs OBX, LXRX, ABUS: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Silence Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Silence Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Silence Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Silence Therapeutics's Shiller PE Ratio falls into.


SLN
36GF Score
Silence Therapeutics PLC SLN
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Silence Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Silence Therapeutics's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, Silence Therapeutics's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.27/142.3000*142.3000
=-0.270

Current CPI (Jun. 2026) = 142.3000.

Silence Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201212 0.000 97.300 0.000
201306 0.000 98.000 0.000
201312 0.000 99.200 0.000
201406 0.000 99.800 0.000
201412 0.000 99.900 0.000
201506 0.000 100.100 0.000
201512 0.000 100.400 0.000
201606 0.000 101.000 0.000
201612 0.000 102.200 0.000
201706 0.000 103.500 0.000
201712 0.000 105.000 0.000
201806 0.000 105.900 0.000
201812 0.000 107.100 0.000
201906 0.000 107.900 0.000
201912 0.000 108.500 0.000
202006 0.000 108.800 0.000
202009 -0.425 109.200 -0.554
202012 -0.674 109.400 -0.877
202103 -0.400 109.700 -0.519
202106 -0.544 111.400 -0.695
202109 -0.447 112.400 -0.566
202112 -0.432 114.700 -0.536
202203 -0.339 116.500 -0.414
202206 -0.484 120.500 -0.572
202209 -0.241 122.300 -0.280
202212 -0.595 125.300 -0.676
202303 -0.353 126.800 -0.396
202306 -0.363 129.400 -0.399
202309 -0.271 130.100 -0.296
202312 -0.504 130.500 -0.550
202403 -0.060 131.600 -0.065
202406 -0.420 133.000 -0.449
202409 -0.750 133.500 -0.799
202412 0.270 135.100 0.284
202503 -0.600 136.100 -0.627
202506 -0.570 138.400 -0.586
202509 -0.450 138.900 -0.461
202512 -0.270 139.900 -0.275
202603 -0.330 140.800 -0.334
202606 -0.270 142.300 -0.270

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Silence Therapeutics (SLN) Overvalued in 2026?

Based on GuruFocus' analysis, Silence Therapeutics stock appears to be overvalued. The current stock price of $13.05 is trading 18542.9% above its estimated GF Value™ of $0.07. GuruFocus considers Silence Therapeutics to be Significantly Overvalued.

Key valuation signals for SLN:

  • Shiller PE Ratio:
  • GF Value™: $0.07 vs. price of $13.05 (18542.9% above fair value)
  • GF Score™: 36/100 with 8 warning signs

No single metric tells the full story. See the SLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Silence Therapeutics Business Description

Other Exchanges SLNCF:USAXRP2:Germany
Address 12 Hammersmith Grove, London, GBR, W6 7AP
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
36GF Score

Get the complete analysis for SLN

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.05
Price
$0.07
GF Value